Immunotherapy Breakthrough Hodgkin Lymphoma Patients (VIDEO)

Dana-Farber Cancer Institute

Caption

Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission, reported in a study published in the New England Journal of Medicine and presented at the annual meeting of the American Society of Hematology.

Credit

Dana-Farber Cancer Institue

Usage Restrictions

EMBARGOED until Saturday, Dec. 6, 2014, 1 p.m. ET

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.